You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme

    SBC: BEXION PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Our goal is to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme GBM high grade glioma a deadly and invasive brain tumor with no effective treatment Of the patients expected to be diagnosed with GBM this year most will succumb within a year There is an urgent demand for an efficac ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Magnetic Flow Sorter for Pancreatic Islet Isolation

    SBC: TECHSHOT, INC.            Topic: 200

    DESCRIPTION provided by applicant Techshot Inc has successfully completed SBIR Phase I and Phase II research demonstrating that magnetically labeled porcine islets of Langerhans can be isolated from contaminating exocrine tissue by flow sorting using a quadrupole magnetic separator andquot Quadrasepandquot designed for that purpose Magnetically sorted islets are superior in morphology and ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Hollow Fiber Catheter for Drug Delivery into the Prostate

    SBC: TWIN STAR TDS, LLC            Topic: 300

    DESCRIPTION provided by applicant The significance of the proposed research is based on the growing demand for healthcare resources to treat and manage prostatic disease particularly benign prostatic hyperplasia BPH and cancer Both the incidence and cost of treatment for BPH and its complications are growing rapidly with the aging U S population prostate cancer is the second leading cau ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Selection-driven plant metabolites for treatment of CNS diseases

    SBC: NAPROGENIX, INC.            Topic: 150

    DESCRIPTION provided by applicant This project aims to demonstrate that the evolution of plant biosynthetic pathways can be accelerated and driven to favor the synthesis of ligands which interact with a specific human target protein This is achieved by subjecting mutant plant cells to selection pressures favoring the survival of mutants with the phenotype of interest As an example this appro ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of

    SBC: AARDEN PHARMACEUTICALS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of tuberculosis Aarden Pharmaceuticals Project Summary/Abstract The need exists for a new, breakthrough therapeutic for tuberculosis (TB). Current treatment regimens with toxic chemotherapeutic drugs are too long, causing poor compliance which results in reduced efficacy and the emer ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Intelligent and Automatic Image Segmentation Software for High ThroughputAnalysi

    SBC: CytoInformatics LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): It is well established that aging and many chronic diseases, such as cancer and heart failure, are associated with significant losses in skeletal muscle mass and strength in humans. There is agreement across the musclebiology community that important morphological characteristics of muscle fibers, such as fiber area, the number and position of myonuclei, cellul ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government